花园生物(300401) - 2015 Q3 - 季度财报

Financial Performance - Total operating revenue for the reporting period was CNY 30,730,337.65, down 16.50% year-on-year[6]. - Net profit attributable to shareholders was CNY -1,609,719.58, a decline of 116.68% compared to the same period last year[6]. - Basic earnings per share were CNY -0.01, a decrease of 120.00% year-on-year[6]. - Total profit decreased by 65.28% to ¥10,989,988.80, primarily due to a halt in cholesterol production line renovations and a significant drop in VD3 product prices[15]. - Net profit fell by 62.14% to ¥9,244,183.55 compared to ¥24,418,963.58 in the same period last year[15]. - The company reported a revenue of 10,195.09 million CNY for the third quarter, a decrease of 6.59% compared to the same period last year[17]. - The total profit for the period was 1,099.00 million CNY, down 65.28% year-on-year[17]. - The net profit attributable to shareholders was 924.42 million CNY, representing a decrease of 62.14% compared to the previous year[17]. - The company experienced a 62.19% decline in profit for the first three quarters of 2015 compared to the same period last year, primarily due to increased costs from imported cholesterol and a drop in the selling price of vitamin D3[32]. Cash Flow and Assets - The net cash flow from operating activities increased by 268.25% to CNY 34,011,776.56 year-to-date[6]. - Cash flow from operating activities showed a net inflow of 34,011,776.56 CNY, a significant improvement from a net outflow of 20,215,177.99 CNY in the same period last year[18]. - Cash outflow for purchasing goods and services was 65,773,808.11 CNY, down 48.31% year-on-year due to reduced procurement[18]. - Investment activities resulted in a net cash outflow of 44,645,619.06 CNY, a decline of 292.48% compared to the previous year[18]. - The total cash and cash equivalents at the end of Q3 2015 stood at ¥46,735,444.82, down from ¥235,904,203.37 at the end of Q3 2014[61]. - The cash outflow for purchasing goods and services was ¥101,186,094.95, down from ¥169,101,361.05 in the same quarter last year, reflecting a reduction of about 40.2%[63]. - The cash inflow from investment activities was ¥214,317,389.90, compared to ¥286,097,090.52 in the previous year, showing a decrease of approximately 25%[64]. - The cash outflow for investment activities totaled ¥265,636,653.11, an increase from ¥223,544,650.74 in the same period last year, representing an increase of about 18.8%[64]. Shareholder Information - The total number of shareholders at the end of the reporting period was 12,280[10]. - The top shareholder, Zhejiang Xiangyun Technology Co., Ltd., holds 38.41% of the shares, with 69,678,840 shares pledged[11]. - The company did not engage in any repurchase transactions among the top shareholders during the reporting period[14]. - The company plans to issue no more than 50 million shares to raise up to CNY 540 million for expanding its vitamin D3 industry chain[9]. - The company plans to distribute at least 20% of the annual distributable profits in cash dividends[23]. - The company’s controlling shareholder will voluntarily deposit their dividend income with the company as a guarantee for fulfilling commitments[24]. Investment and Development - The company's construction in progress increased by 71.06% to ¥189,669,305.74, reflecting ongoing investments in fundraising projects[15]. - Development expenses surged by 396.33% to ¥5,135,511.18 due to increased costs for trial materials and labor for the 25-hydroxycholesterol project[15]. - The project for comprehensive utilization of lanolin has been fully completed with a total investment of CNY 4,200 million, achieving 100.00% of the planned progress[28]. - The project for producing 100 tons of feed-grade 25-hydroxyvitamin D3 has also been completed with a total investment of CNY 8,792.9 million, achieving 100.98% of the planned progress[28]. Market and Product Sensitivity - Vitamin D3 products account for over 90% of the company's main business revenue, making it highly sensitive to price fluctuations[9]. - The company faced challenges due to high procurement costs for imported raw materials, affecting overall profitability[17]. - The company experienced a significant drop in the market price of its main product, Vitamin D3, impacting net profit negatively[18]. Equity and Liabilities - Total assets at the end of the reporting period were CNY 745,238,630.57, a decrease of 1.32% compared to the previous year[6]. - The company's current assets decreased from CNY 418,172,487.34 to CNY 333,441,585.27, representing a decline of approximately 20.3%[38]. - Total liabilities decreased from CNY 46,223,680.77 to CNY 36,044,215.36, a reduction of approximately 22.1%[40]. - The company's equity attributable to shareholders increased slightly from CNY 709,020,231.14 to CNY 709,194,415.21, indicating a marginal growth[41]. - Total liabilities increased to ¥77,407,353.94, compared to ¥47,784,389.89 in the previous year, reflecting a rise of 62.2%[47].